Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medpace Holdings, Inc. (“Medpace” or “the Company”) (NASDAQ: MEDP). Investors who purchased Medpace securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/MEDP.

Investigation Details

On October 21, 2024, Medpace reported its third quarter 2024 financial results, which cut its revenue guidance for the full year. During an investor call the next day, the Company described higher cancellations in the third quarter. The Company’s net book-to-bill ratio was a low 1.00 for the third quarter, below analyst estimates and historically low compared to its past performance. Following this news, Medpace stock dropped.

What's Next?

If you are aware of any facts relating to this investigation or purchased Medpace securities, you can assist this investigation by visiting the firm’s site: bgandg.com/MEDP. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241031033366/en/